Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Natalie Vokes Natalie Vokes, MD
CONTACT
Lead
M.D. Anderson Cancer Center
Primary Objectives: Phase I: To evaluate the safety of navlimetostat in combination with pumitamig. Phase II: To evaluate the efficacy of navlimetostat in combination with pumitamig. Secondary Objectives: * To evaluate toxicity and tolerability of navlimetostat in combination with pumitamig. * To evaluate efficacy outcomes including disease control rate, progression-free survival, overall survival, and duration of response. * To compare the efficacy of the combination in patients with prior ICI exposure and those without (treated with targeted therapy and/or chemotherapy). Exploratory Objectives: * To identify potential biomarkers of resistance and sensitivity including MTAP expression (IHC), ctDNA changes as a predictive biomarker for detecting early progression and/or poor response to therapy, and early changes in cytokines and circulating immune cells as markers of treatment response * To investigate the TME in MTAP-deficient NSCLC before and after treatment
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted